title: A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells.
abstract: Tumor resistance due to multiple mechanisms seriously hinders the efficacy of chemotherapy drugs such as paclitaxel. The most widely studied P-glycoprotein inhibitors still have limited ability to reverse resistance in the clinic. In this study, NPB304, a novel Sinenxan A (SIA) derivative, was found to significantly sensitize resistant breast cancer cells to paclitaxel in vitro and in vivo. Treatment with NPB304 increased paclitaxel-induced apoptosis in a p53-dependent manner through PARP cleavage. Importantly, NPB304 enhanced the antitumor effect of paclitaxel in resistant breast tumor xenografts in nude mice without significantly affecting weight loss. NPB304 regulated cell resistance through inhibition of MAPK pathway components, including p-ERK and p-p38. Moreover, NPB304 increased paclitaxel accumulation by affecting P-gp function. In addition to increasing Rhodamine 123 accumulation, NPB304 promoted bidirectional permeability but decreased the efflux ratio of paclitaxel in a Caco-2 monolayer model, thereby increasing the intracellular concentration of paclitaxel. Similarly, NPB304 increased the concentration of paclitaxel in the resistant tumor tissue. Hence, NPB304 is a novel compound that promotes the sensitization of resistant cells to paclitaxel through multiple mechanisms and has the potential for use in combination therapies to treat resistant breast cancer.
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Mei
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Xie
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Feng
authors.initials: F
authors.lastname: You
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Jungui
authors.initials: J
authors.lastname: Dai
authors.affiliation: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City, China.
authors.forename: Xiaoguang
authors.initials: X
authors.lastname: Chen
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism; D000085:Acetates / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004224:Diterpenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004357:Drug Synergism; D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D017239:Paclitaxel / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000085:Acetates; D000970:Antineoplastic Agents; D004224:Diterpenes; C484850:sinenxan A; D017239:Paclitaxel
references.citation: Mol Med Rep. 2011 Jul-Aug;4(4):739-46
references.pmid: 21584498
references.citation: Cancer Chemother Pharmacol. 2005 Oct;56(4):379-90
references.pmid: 15875185
references.citation: Int J Cancer. 2013 Jan 1;132(1):224-35
references.pmid: 22623106
references.citation: Cell Death Differ. 2003 Apr;10(4):431-42
references.pmid: 12719720
references.citation: Bioorg Med Chem Lett. 2010 Sep 15;20(18):5418-21
references.pmid: 20709551
references.citation: Br J Haematol. 2010 May;149(4):537-49
references.pmid: 20331454
references.citation: Adv Exp Med Biol. 2013;765:279-286
references.pmid: 22879045
references.citation: Drug Resist Updat. 2012 Feb-Apr;15(1-2):50-61
references.pmid: 22464282
references.citation: Cancer Chemother Pharmacol. 2010 Oct;66(5):851-9
references.pmid: 20052473
references.citation: Nat Rev Cancer. 2004 Dec;4(12):937-47
references.pmid: 15573115
references.citation: J Biol Chem. 2000 Dec 15;275(50):38953-6
references.pmid: 11038347
references.citation: Cancer Res. 1998 Aug 15;58(16):3620-6
references.pmid: 9721870
references.citation: Ann Med. 2006;38(3):200-11
references.pmid: 16720434
references.citation: Cancer Chemother Pharmacol. 2013 Jun;71(6):1453-62
references.pmid: 23558944
references.citation: Curr Top Med Chem. 2009;9(17):1625-35
references.pmid: 19903158
references.citation: Ann Oncol. 1994;5 Suppl 6:S3-6
references.pmid: 7865431
references.citation: Gynecol Oncol. 2004 Apr;93(1):98-106
references.pmid: 15047220
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):230-9
references.pmid: 18172275
references.citation: Curr Pharm Des. 2013;19(5):883-94
references.pmid: 22973957
references.citation: Expert Opin Ther Targets. 2012 Jan;16(1):103-19
references.pmid: 22239440
references.citation: Cancer Res. 2005 Apr 1;65(7):2854-60
references.pmid: 15805287
references.citation: Cell Death Dis. 2013 Apr 11;4:e589
references.pmid: 23579276
references.citation: Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
references.pmid: 17126425
references.citation: Cancer Res. 2004 Oct 1;64(19):7117-26
references.pmid: 15466208
references.citation: J Biol Chem. 1998 Jul 17;273(29):18623-32
references.pmid: 9660836
references.citation: Carcinogenesis. 2002 Nov;23(11):1831-8
references.pmid: 12419831
references.citation: Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1935-42
references.pmid: 20523987
references.citation: Int J Cancer. 2008 Dec 1;123(11):2532-42
references.pmid: 18729196
references.citation: Clin Chem Lab Med. 2002 Sep;40(9):918-25
references.pmid: 12435109
references.citation: J Med Chem. 2005 Mar 24;48(6):2218-28
references.pmid: 15771464
references.citation: J Natl Cancer Inst. 1997 Jul 2;89(13):917-31
references.pmid: 9214671
references.citation: Mol Pharmacol. 2001 Aug;60(2):290-301
references.pmid: 11455016
references.citation: Mol Cancer Ther. 2013 Feb;12(2):131-40
references.pmid: 23270924
references.citation: Cancer Control. 2003 Mar-Apr;10(2):159-65
references.pmid: 12712010
references.citation: Curr Med Chem. 2006;13(16):1859-76
references.pmid: 16842198
references.citation: Cell Death Dis. 2013 May 23;4:e641
references.pmid: 23703386
references.citation: Front Biosci. 2008 May 01;13:5138-54
references.pmid: 18508576
references.citation: Biol Pharm Bull. 2012;35(12):2170-9
references.pmid: 23207769
references.citation: Mol Biotechnol. 2010 Nov;46(3):308-16
references.pmid: 20717753
references.citation: FEBS J. 2010 Aug;277(16):3437-48
references.pmid: 20646066
references.citation: Nature. 2007 Apr 12;446(7137):749-57
references.pmid: 17429392
references.citation: PLoS One. 2013;8(1):e54181
references.pmid: 23349819
references.citation: Int J Cancer. 1999 Oct 8;83(2):151-6
references.pmid: 10471519
references.citation: Expert Opin Pharmacother. 2002 Jun;3(6):755-66
references.pmid: 12036415
references.citation: Oncotarget. 2012 Oct;3(10):1068-111
references.pmid: 23085539
references.citation: Drug Resist Updat. 2003 Apr;6(2):71-84
references.pmid: 12729805
references.citation: Chem Pharm Bull (Tokyo). 2011;59(8):1038-41
references.pmid: 21804250
references.citation: J Natl Cancer Inst. 1996 Sep 18;88(18):1308-14
references.pmid: 8797771
references.citation: Eur J Pharm Sci. 2001 Aug;14(1):29-36
references.pmid: 11457647
references.citation: Mol Cancer Ther. 2003 Nov;2(11):1195-205
references.pmid: 14617793
references.citation: Leukemia. 1998 Dec;12(12):1843-50
references.pmid: 9844914
references.citation: Drug Resist Updat. 2007 Jun;10(3):81-100
references.pmid: 17482503
references.citation: Leukemia. 2011 Jul;25(7):1080-94
references.pmid: 21494257
references.citation: Nature. 2000 Nov 16;408(6810):307-10
references.pmid: 11099028
references.citation: Br J Pharmacol. 2012 Jul;166(5):1669-83
references.pmid: 22233293
references.citation: Cell Mol Life Sci. 2008 Oct;65(20):3145-67
references.pmid: 18581055
references.citation: Breast Cancer Res. 2001;3(3):150-3
references.pmid: 11305949
references.citation: Cancer Metastasis Rev. 2013 Jun;32(1-2):211-27
references.pmid: 23093326